Larimar Therapeutics (LRMR) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 97.6% versus a loss of 44.0%. Over five years, OBIO leads with a -41.8% price change compared with -77.7% for LRMR. Orchestra BioMed is the larger company by market cap ($349.5 million vs $282.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | OBIO |
|---|---|---|
| Share price | $2.72 | $5.82 |
| Market cap | $282.04M | $349.51M |
| 1-day change | +0.56% | +1.48% |
| YTD return | -29.13% | +38.07% |
| 1-year return | -43.98% | +97.59% |
| 5-year return | -77.72% | -41.83% |
| EPS (TTM) | $-1.99 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $6.50 |
| 52-week low | $2.61 | $2.86 |
| Distance from 52-week high | -57.71% | -10.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +430.39% | +113.76% |
| Average volume | 1.27M | 299.84K |
| Shares outstanding | 103.88M | 60.11M |
| Employees | 71 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed LRMR by 141.6 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
LRMR vs OBIO FAQ
Which is bigger, Larimar Therapeutics or Orchestra BioMed?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $349.51M compared with $282.04M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, LRMR or OBIO?
OBIO returned +97.59% over the past 12 months, compared with -43.98% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Orchestra BioMed in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Larimar Therapeutics and Medicinal Chemicals and Botanical Products for Orchestra BioMed.